<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03613935</url>
  </required_header>
  <id_info>
    <org_study_id>17.19.BIO</org_study_id>
    <nct_id>NCT03613935</nct_id>
  </id_info>
  <brief_title>Effect of Changes in Glucose Intake and Sweet Perception on Post Prandial Glycaemia</brief_title>
  <official_title>Effect of Changes in Glucose Intake and Sweet Perception on Post Prandial Glycaemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nestlé</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Nestlé</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Sugar-sweetened beverages are the main source of added sugars in most Westernized countries,&#xD;
      and for this reason constitute a primary target for sugar reduction by many companies,&#xD;
      including Nestlé. Instead of using high-intensity sweeteners which are non-caloric in nature,&#xD;
      an alternative would be to reduce sugars without altering sweetness.&#xD;
&#xD;
      In this protocol, the general goal is to investigate the relative contribution of sweet taste&#xD;
      perception and sugar intake on post-prandial glucose response. 4 different nutritional&#xD;
      products will be tested by 16 healthy subjects in a crossover design.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      After enrollment, participants will be asked to come to the investigational site 6 times for:&#xD;
&#xD;
        -  two sensory tests dedicated to assess the sensory capacity of the participants from the&#xD;
           same sensory test repeated twice, for better consistency.&#xD;
&#xD;
        -  4 testing visits for a 3-h blood kinetics after each product intake. These visits will&#xD;
           be scheduled on different days separated by a washout period of at least one week.&#xD;
           Outcomes will be glycemia and insulinemia.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 19, 2018</start_date>
  <completion_date type="Actual">April 20, 2018</completion_date>
  <primary_completion_date type="Actual">April 20, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>This is a monocentric, controlled, randomized, open, complete crossover study design</intervention_model_description>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incremental Area under the Curve (iAUC) of plasma glucose</measure>
    <time_frame>0 to 3 hours post product intake</time_frame>
    <description>Area under the curve</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incremental Area under the Curve (iAUC) of plasma insulin</measure>
    <time_frame>0 to 3 hours post product intake</time_frame>
    <description>Area under the curve</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax of plasma glucose</measure>
    <time_frame>between 0 and 3 hours post product intake</time_frame>
    <description>Maximal concentration of plasma glucose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax of plasma insulin</measure>
    <time_frame>between 0 and 3 hours post product intake</time_frame>
    <description>Maximal concentration of plasma insulin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tmax of plasma glucose</measure>
    <time_frame>between 0 and 3 hours post product intake</time_frame>
    <description>Time (min) for maximal concentration of plasma glucose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tmax of plasma insulin</measure>
    <time_frame>between 0 and 3 hours post product intake</time_frame>
    <description>Time (min) for maximal concentration of plasma insulin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sensory tasting capacity</measure>
    <time_frame>immediately after product intake</time_frame>
    <description>Assessment of the sweetness of two beverages versus control through a questionnaire</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">16</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Product 1</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Normal glucose, isosweet, homogeneous: 43 g glucose beverage, with a 43 g glucose equivalent sweetness homogenously delivered</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Product 2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Low glucose, isosweet, heterogeneous: 30 g glucose beverage with 43 g glucose equivalent sweetness heterogeneously delivered</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Product 3</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Low glucose, less sweet, homogeneous: 30 g glucose beverage with a 30 g glucose equivalent sweetness homogenously delivered</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Product 4</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Low glucose+sucralose, isosweet, homogeneous: 30 g glucose + 18 mg sucralose beverage with a 43 g glucose equivalent sweetness homogenously delivered</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Product 1</intervention_name>
    <description>Comparison with products 2, 3, and 4</description>
    <arm_group_label>Product 2</arm_group_label>
    <arm_group_label>Product 3</arm_group_label>
    <arm_group_label>Product 4</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Product 2</intervention_name>
    <description>Comparison with products 1, 3, and 4</description>
    <arm_group_label>Product 1</arm_group_label>
    <arm_group_label>Product 3</arm_group_label>
    <arm_group_label>Product 4</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Product 3</intervention_name>
    <description>Comparison with products 1, 2, and 4</description>
    <arm_group_label>Product 1</arm_group_label>
    <arm_group_label>Product 2</arm_group_label>
    <arm_group_label>Product 4</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Product 4</intervention_name>
    <description>Comparison with products 1, 2, and 3</description>
    <arm_group_label>Product 1</arm_group_label>
    <arm_group_label>Product 2</arm_group_label>
    <arm_group_label>Product 3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  BMI between 18.5 and 29.9 kg/m2&#xD;
&#xD;
          -  Fasting capillary blood glucose level ≤ 7 mmol/L&#xD;
&#xD;
          -  Able to understand and sign an informed consent form&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnancy on anamnesis&#xD;
&#xD;
          -  Lactating mothers&#xD;
&#xD;
          -  Individuals undergoing either dietary or exercise mediated weight loss program&#xD;
             prescribed by a health care professional&#xD;
&#xD;
          -  Medically-treated diabetes mellitus or use of anti-hyperglycemic drugs or insulin&#xD;
&#xD;
          -  Family history of type 2 diabetes (parents)&#xD;
&#xD;
          -  Any other metabolic disease possibly impacting the postprandial glucose and insulin&#xD;
             response (to the opinion of the medical doctor)&#xD;
&#xD;
          -  Known ageusia or other tasting trouble&#xD;
&#xD;
          -  Chronic intake of medications known to affect glucose tolerance to the opinion of the&#xD;
             investigator (steroids, protease inhibitors, antidepressants, anxiolytic, or&#xD;
             antipsychotics)&#xD;
&#xD;
          -  Presence of disease or intake of drug that affects digestion and absorption of&#xD;
             nutrients, to the opinion of the medical doctor&#xD;
&#xD;
          -  Major medical/surgical event requiring hospitalisation in the last 3 months&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Maurice Beaumont, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Nestlé</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Nestlé Research Center</name>
      <address>
        <city>Lausanne</city>
        <zip>1000</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>August 2018</verification_date>
  <study_first_submitted>July 9, 2018</study_first_submitted>
  <study_first_submitted_qc>August 2, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 3, 2018</study_first_posted>
  <last_update_submitted>August 2, 2018</last_update_submitted>
  <last_update_submitted_qc>August 2, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">August 3, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

